Benign prostatic hyperplasia (BPH) is a common condition in men over the age of 50. It is characterized by an enlarged prostate, which can cause symptoms such as difficulty urinating, a weak urine stream, and a frequent need to urinate. BPH is not a life-threatening condition, but it can be bothersome and interfere with quality of life. Fortunately, there are a number of treatment options available to men with BPH, ranging from lifestyle changes to medications to surgery. In this article, we will explore the various treatment options available for BPH and discuss the pros and cons of each.
Medications are the most common treatment for BPH. Alpha blockers, such as tamsulosin (Flomax) and terazosin (Hytrin), are often the first line of treatment. These medications relax the muscles of the prostate and bladder neck, which helps to improve urinary flow. 5-alpha reductase inhibitors, such as finasteride (Proscar) and dutasteride (Avodart), are also used to treat BPH. These medications reduce the size of the prostate by blocking the conversion of testosterone to dihydrotestosterone, which is a hormone that stimulates prostate growth.
In addition to medications, lifestyle changes can help to reduce the symptoms of BPH. Limiting caffeine and alcohol intake can help to reduce urinary frequency and urgency, as can avoiding drinks that contain bladder irritants such as citrus juices and carbonated beverages. Regular exercise can also help to reduce symptoms, as can reducing stress levels.
If medications and lifestyle changes are not enough to relieve symptoms, surgery may be recommended. Transurethral resection of the prostate (TURP) is the most common surgical procedure for BPH. During this procedure, a portion of the prostate is removed through the urethra, which helps to reduce the size of the prostate and improve urinary flow. Other surgical procedures, such as laser therapy and transurethral incision of the prostate (TUIP), are also available.
As with any medical or surgical procedure, there are potential risks and side effects associated with the treatment of BPH. Alpha blockers can cause dizziness, weakness, and low blood pressure. 5-alpha reductase inhibitors can cause sexual side effects, such as decreased libido and erectile dysfunction. Surgery can cause bleeding, infection, and urinary incontinence. It is important to discuss the potential risks and side effects with your doctor before deciding on a treatment plan.
Benign prostatic hyperplasia is a common condition in men over the age of 50. Fortunately, there are a number of treatment options available, ranging from lifestyle changes to medications to surgery. It is important to discuss the potential risks and side effects with your doctor before deciding on a treatment plan. With the right treatment, men with BPH can lead healthy, active lives.
1.
Breast Cancer Patients Living Longer Post-Medicaid Expansion
2.
Error on the MGUS-Autoimmune Disease Association.
3.
Patients with chronic myeloid leukemia who take nilotinib are at higher risk for diabetes and hyperlipidemia.
4.
The majority of cancer medications that receive expedited approval end up failing confirmatory trials.
5.
Unified Neuro/Psych Residency Program: New Proposal.
1.
Optimizing Melanoma Treatment: Strategies in Diagnosis, Clinical Research, and Physician Training
2.
Hemoglobin C: Understanding its Role in Sickle Cell Disease
3.
Beyond the Human Eye: How AI Is Redefining Brain Cancer Diagnosis Through Advanced Imaging
4.
Understanding Abemaciclib: A Breakthrough Treatment for Breast Cancer
5.
The Growing Challenge of Haematological Malignancies in Older Adults
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
2.
Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII
4.
A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC
5.
Efficient Management of First line ALK-rearranged NSCLC - Part VI
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation